knowledge -WSS

knowledge

author：entertainment 2025-09-29 14:00:33 - browse：2169

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Change Healthcare can notify patients about the breach, HHS says

leisure time

WSS

In 'major milestone,' FDA approves first cell therapy for solid tumors

ASCO: AstraZeneca says CAR

See how much Covid

How to increase colonoscopy rates? Looks like an AI can help

Ionis drug prevents swelling attacks due to hereditary angioedema

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

entertainment

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

As demand for Covid shots wanes, Moderna seeks its next success

NIH documents show early flaws of $1.6 billion long Covid program

Alkermes shareholders re

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

NIH documents show early flaws of $1.6 billion long Covid program

Psychedelics group wrestles with new pharma identity

MD Anderson's Padmanee Sharma responds to research credit suit

leisure time

ASCO: AstraZeneca says CAR

ASCO: AstraZeneca says CAR

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Change Healthcare can notify patients about the breach, HHS says

Shifting the focus from loneliness to social health

With trial win, GSK could get blood cancer drug back on market

leisure time

leisure time

focus

Wikipedia